Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/31/09
End: 07/31/11
Due: 07/31/12
Phase: N/A
Priority: Normal
Start: 11/30/11
End: 05/31/18
Due: 05/31/19
Phase: N/A
Priority: Normal
Start: 12/31/09
End: 02/28/11
Due: 02/28/12
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL | NCT01047683 | Amarin Pharma Inc. | user2@example.com | None | 2009-12-31 | 2011-07-31 | 2012-07-31 | - | - | 2025-07-14 |
| A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin | NCT01492361 | Amarin Pharma Inc. | user2@example.com | None | 2011-11-30 | 2018-05-31 | 2019-05-31 | - | - | 2025-07-14 |
| Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) | NCT01047501 | Amarin Pharma Inc. | user2@example.com | None | 2009-12-31 | 2011-02-28 | 2012-02-28 | - | - | 2025-07-14 |